Evidence-Based Selection of Inhaled Corticosteroid for Treatment of Chronic Asthma

REFERENCES

• Global Strategy for Asthma Management and Prevention, www.ginasthma.org NIH publication 02-3659 Issued January 1995 (updated 2002). Management Segment (Chapter 7) updated 2005 from the 2004 document. The GINA reports are available on
   Google Scholar
• Barnes P J, Adcock I M. Transcription factors and asthma. Eur Respir J 1998; 12: 221–234
   PubMed Web of Science ®Google Scholar
• Lipworth B J. Systemic adverse effects of inhaled corticosteroid therapy: a systematic review and meta-analysis. Arch Intern Med 1999; 159: 941–955
   PubMed Web of Science ®Google Scholar
• Roland N J, Bhalla R K, Earis J. The local side effects of inhaled corticosteroids: current understanding and review of the literature. Chest 2004; 126: 213–219
   PubMed Web of Science ®Google Scholar
• Guyatt G, Gutterman D, Baumann M H, Addrizzo-Harris D, Hylek E M, Phillips B, Raskob G, Lewis S Z, Schunemann H. Grading strength of recommendations and quality of evidence in clinical guidelines. Report from an American College of Chest Physicians Task Force. Chest 2006; 129: 174–181
   PubMed Web of Science ®Google Scholar
• Allen D B, Bielory L, Derendorf H, Dluhy R, Colice G L, Szefler S J. Inhaled corticosteroids: past lessons and future issues. J Allergy Clin Immunol 2003; 112: S1–S40, (suppl 1)
   PubMedGoogle Scholar
• Rohatagi S, Appajosyula S, Derendorf H, et al. Risk-benefit value of inhaled glucocorticoids: a pharmacokinetic/pharmacodynamic perspective. J Clin Pharmacol 2004; 44: 37–47
   PubMed Web of Science ®Google Scholar
• Labiris N R, Dolovich M B. Pulmonary drug delivery. Part I: Physiological factors affecting therapeutic effectiveness of aerosolized medications. Brit J Clin Pharmacol 2003; 56: 588–599
   PubMed Web of Science ®Google Scholar
• Barnes P J, Pedersen S, Busse W W. Efficacy and safety of inhaled corticosteroids. New developments. Am JRespir Crit Care Med 1998; 157: S1–S53, (Pt 2)
   Google Scholar
• Zeidler M, Corren J. Hydrofluoroalkane formulations of inhaled corticosteroids for the treatment of asthma. Treat Respir Med 2004; 3: 35–44
   PubMedGoogle Scholar
• Rohdewald P J. Comparison of clinical efficacy of inhaled glucocorticoids. Arzneimittelforschung 1998; 48: 789–796
   PubMed Web of Science ®Google Scholar
• Bronsky E, Korenblat P, Harris A G, Chen R. Comparative clinical study of inhaled beclomethasone dipropionate and triamcinolone acetonide in persistent asthma. Ann Allergy Asthma Immunol 1998; 80: 295–302
   PubMedGoogle Scholar
• Ederle K. Multicentre Study Group. Improved control of asthma symptoms with a reduced dose of HFA-BDP extrafine aerosol: An open-label, randomised study. Eur Rev Med Pharmacol Sci 2003; 7: 45–55
   Google Scholar
• Pethica B D, Penrose A, MacKenzie D, Hall J, Beasley R, Tilyard M. Comparison of potency of inhaled beclomethasone and budesonide in New Zealand: retrospective study of computerised general practice records. Br Med J 1998; 317(7164)986–990
   Google Scholar
• Berkowitz R, Rashelefski G, Harris A G, Chen R. A comparison of triamcinolone acetonide MDI with a built-in tube extender and beclomethasone dipropionate MDI in adult asthmatics. Chest 1998; 114: 757–765
   PubMedGoogle Scholar
• Hartley T F, Romero R C. Evaluation of aerosolized triamcinolone acetonide as a replacement for aerosolized beclomethasone dipropionate. J Asthma. 1986; 23: 139–143
   PubMed Web of Science ®Google Scholar
• Dry J, Sors C, Gervais P, van Straaten L, Perrin-Fayolle M, Paramelle B. Comparison of flunisolide inhaler and beclomethasone dipropionate inhaler in bronchial asthma. J Int Med Res 1985; 13: 289–293
   Google Scholar
• Miyamoto T, Takahashi T, Nakajima S, Makino S, Yamakido M, Mano K, Nakashima M, Tollemar U, Selroos O. On behalf of a Japanese Pulmicort Turbuhaler Study Group. Efficacy of budesonide Turbuhaler compared with that of beclomethasone dipropionate pMDI in Japanese patients with moderately persistent asthma. Respirology 2001; 6: 27–35
   Google Scholar
• Ohaju-Obodo J O, Chukwu C, Okpapi J, Egbagbe E, Ige M O, Chukwuka C, Adedapo D A. Comparison of the efficacy and safety of budesonide turbuhaler administered once daily with twice the dose of beclomethasone dipropionate using pressurised metered dose inhaler in patients with mild to moderate asthma. West Afr J Med 2005; 24: 190–195
   Google Scholar
• Chervinsky P, Nelson H S, Bernstein D I, Berkowitz R A, Siegel S C. Comparison of mometasone furoate administered by metered dose inhaler with beclomethasone dipropionate. Int J Clin Pract 2002; 56: 419–425
   Google Scholar
• Chrousos G P, Ghaly L, Shedden A, Iezzoni D G, Harris A G. Effects of mometasone furoate dry powder inhaler and beclomethasone dipropionate hydrofluoroalkane and chlorofluorocarbon on the hypothalamic-pituitary-adrenal axis in asthmatic subjects. Chest 2005; 128: 70–77
   PubMed Web of Science ®Google Scholar
• Nathan R A, Nayak A S, Graft D F, Lawrence M, Picone F J, Ahmed T, Wolfe J, Vanderwalker M L, Nolop K B, Harrison J E. Mometasone furoate: efficacy and safety in moderate asthma compared with beclomethasone dipropionate. Ann Allergy Asthma Immunol 2001; 86: 203–210
   PubMed Web of Science ®Google Scholar
• Bernstein D I, Berkowitz R B, Chervinsky P, Dvorin D J, Finn A F, Gross G N, Karetzky M, Kemp J P, Laforce C, Lumry W, Mendelson L M, Nelson H, Pearlman D, Rachelefsky G, Ratner P, Repsher L, Segal A T, Selner J C, Settipane G A, Wanderer A, Cuss F M, Nolop K B, Harrison J E. Dose-ranging study of a new steroid for asthma: mometasone furoate dry powder inhaler. Respir Med 1999; 93: 603–612
   PubMed Web of Science ®Google Scholar
• Adams N, Bestall J M, Jones P W. Inhaled beclomethasone versus budesonide for chronic asthma. The Cochrane Database of Systematic Reviews 2000, Issue 1: CD003530. DOI: 10.1002/14651858.CD003530
   Google Scholar
• Delacourt C, Dutau G, Lefrancois G, Clerson P. Beclospin. Clinical Development Group. Comparison of the efficacy and safety of nebulized beclometasone dipropionate and budesonide in severe persistent childhood asthma. Respir Med 2003; 97: S27–33, (suppl B)
   Google Scholar
• Kaur C, Bansal S K, Chhabra S K. Study on serum and urinary cortisol levels of asthmatic patients after treatment with high dose inhaled beclomethasone dipropionate or budesonide. Indian J Chest Dis Allied Sci 2005; 47: 89–95
   Google Scholar
• Reichel W, Dahl R, Ringdal N, Zetterstrom O, van den Elshout F J, Laitinen L A. Extrafine beclomethasone dipropionate breath-actuated inhaler (400 micrograms/day) versus budesonide dry powder inhaler (800 micrograms/day) in asthma. Int J Clin Pract 2001; 55: 100–106
   PubMedGoogle Scholar
• Davies B. A comparison of beclomethasone dipropionate and budesonide in the treatment of asthma. Br J Clin Pract 1993; 47: 87–93
   Google Scholar
• Terzano C, Ricci A, Burinschi V, Nekam K, Lahovsky J. Comparison of the efficacy of beclometasone dipropionate and fluticasone propionate suspensions for nebulization in adult patients with persistent asthma. Respir Med 2003; 97: S35–40, (suppl B)
   Google Scholar
• Barnes N C, Hallett C, Harris T A. Clinical experience with fluticasone propionate in asthma: a meta-analysis of efficacy and systemic activity compared with budesonide and beclomethasone dipropionate at half the microgram dose or less. Respir Med 1998; 92: 95–104
   PubMed Web of Science ®Google Scholar
• Lasseron T, Cates C, Jones A B, Steele E H, White J. Fluticasone versus HFA-beclomethasone dipropionate for chronic asthma in adults and children. Cochrane Database Syst Rev 2005, 4, CD005309
   Google Scholar
• Adams N, Bestall J, Lasserson T, Jones P W. Inhaled fluticasone versus inhaled beclomethasone or inhaled budesonide for chronic asthma in adults and children. Cochrane Database Syst Rev 2005, 2, CD002310
   Google Scholar
• Frezza G, Terra-Filho J, Martinez J AB, Vianna E O. Rapid effect of inhaled steroids on nocturnal worsening of asthma. Thorax 2003; 58: 632–633
   Google Scholar
• Stoloff S W, Srebro S H, Edwards L D, Johnson M C, Rickard K A. Improved asthma control after changing from low-to-medium doses of other inhaled corticosteroids to low-dose fluticasone propionate. MedGenMed 2001; 3: 2, www.medscape.com/viewarticle/408139 Accessed on 16 June 2005
   Google Scholar
• Suzuki T, Hasegawa T, Suzuki E, Sasahara K, Kawada T, Koya T, Akazawa K, Satoh H, Gejyo F. Efficacy of fluticasone propionate compared with beclomethasone dipropionate in bronchial asthma: improvement in compliance and symptoms by fluticasone. Allergy Asthma Proc 2003; 24: 347–351
   Google Scholar
• Leru P, Rascu A, Otelea M, Mohora M, Muscurel C, Galca M, Dinu V. Study of fluticasone propionate efficacy in the treatment of patients with bronchial asthma not controlled by other inhaled corticosteroids. Rom J Intern Med 1998; 36: 105–111
   Google Scholar
• Stempel D A, McLaughlin T, Griffis D L, Stanford R H. Cost analysis of the use of inhaled corticosteroids in the treatment of asthma: a 1-year follow-up. Respir Med 2001; 95: 992–998
   PubMed Web of Science ®Google Scholar
• Holzer S S, Engelhart L, Crown W H, L'Herrou T A, Kennedy S T. Asthma treatment costs using inhaled corticosteroids. Am J Manag Care 1997; 3: 891–897
   PubMedGoogle Scholar
• Kondo T, Tanigaki T, Ono Y, Tazaki G, Urano T, Tajiri S, Eguchi K. Impact of Fluticasone Diskhaler on health-related quality of life in asthmatic patients. Tokai J Exp Clin Med 2002; 27: 79–84
   Google Scholar
• Berend N, Kellett B, Kent N, Sly P D. Collaborative Study Group of the Australian Lung Foundation. Improved safety with equivalent asthma control in adults with chronic severe asthma on high-dose fluticasone propionate. Respirology 2001; 6: 237–246
   PubMedGoogle Scholar
• Rutherford C, Mills R, Gibson P G, Price M J. Improvement in health-related quality of life with fluticasone propionate compared with budesonide or beclomethasone dipropionate in adults with severe asthma. Respirology 2003; 8: 371–375
   PubMed Web of Science ®Google Scholar
• Fukushima C, Matsuse H, Tomari S, Obase Y, Miyazaki Y, Shimoda T, Kohno S. Oral candidiasis associated with inhaled corticosteroid use: comparison of fluticasone and beclomethasone. Ann Allergy Asthma Immunol 2003; 90: 646–651
   PubMed Web of Science ®Google Scholar
• Williamson I J, Matusiewicz S P, Brown P H, Greening A P, Crompton G K. Frequency of voice problems and cough in patients using pressurized aerosol inhaled steroid preparations. Eur Respir J 1995; 8: 590–592
   PubMed Web of Science ®Google Scholar
• Shim C S, Williams M H, Jr. Cough and wheezing from beclomethasone dipropionate aerosol are absent after triamcinolone acetonide. Ann Intern Med 1987; 106: 700–703
   PubMed Web of Science ®Google Scholar
• Watkins K L, Ewanowski S J. Effects of aerosol corticosteroids on the voice: triamcinolone acetonide and beclomethasone dipropionate. J Speech Hear Res 1985; 28: 301–304
   Google Scholar
• Dubus J C, Marguet C, Deschildre A, Mely L, Le Roux P, Brouard J, Huiar L. Local side effects of inhaled corticosteroids in asthmatic children: influence of drug, dose, age, and device. Allergy 2001; 56: 944–948
   PubMed Web of Science ®Google Scholar
• Martin R J, Szefler S J, Chinchilli V M, Kraft M, Dolovich M, Boushey H A, Cherniack R M, Craig T J, Drazen J M, Fagan J K, Fahy J V, Fish J E, Ford J G, Israel E, Kunselman S J, Lazarus S C, Lemanske R F, Jr., Peters S P, SorknessCA for the National Heart. Lung, and Blood Institute's Asthma Clinical Research Network. Systemic effect comparisons of six inhaled corticosteroid preparations. Am J Respir Crit Care Med 2002; 165: 1377–1383
   PubMed Web of Science ®Google Scholar
• Fairfax A, Hall I, Spelman R. A randomized, double-blind comparison of beclomethasone dipropionate extrafine aerosol and fluticasone propionate. Ann Allergy Asthma Immunol 2001; 86: 575–582
   PubMed Web of Science ®Google Scholar
• Niitsuma T, Okita M, Sakurai K, Morita S, Tsuyuguchi M, Matsumura Y, Hayashi T, Koshishi T, Oka K, Homma M. Adrenal function as assessed by low-dose adrenocorticotropin hormone test before and after switching from inhaled beclomethasone dipropionate to inhaled fluticasone propionate. J Asthma 2003; 40: 515–522
   PubMed Web of Science ®Google Scholar
• Rao R, Gregson R K, Jones A C, Miles E A, Campbell M J, Warner J O. Systemic effects of inhaled corticosteroids on growth and bone turnover in childhood asthma: a comparison of fluticasone with beclomethasone. Eur Respir J 1999; 13: 87–94
   PubMed Web of Science ®Google Scholar
• Yiallouros P K, Milner A D, Conway E, Honour J W. Adrenal function and high dose inhaled corticosteroids for asthma. Arch Dis Child 1997; 76: 405–410
   PubMed Web of Science ®Google Scholar
• Lorentzen K A, Van Helmond J L, Bauer K, Langaker K E, Bonifazi F, Harris T A. Fluticasone propionate 1 mg daily and beclomethasone dipropionate 2 mg daily: a comparison over 1 yr. Respir Med 1996; 90: 609–617
   PubMed Web of Science ®Google Scholar
• Leblanc P, Mink S, Keistinen T, Saarelainen P A, Ringdal N, Payne S L. Comparison of fluticasone propionate 200 micrograms/day with beclomethasone dipropionate 400 micrograms/day in adult asthma. Allergy 1994; 49: 380–385
   PubMed Web of Science ®Google Scholar
• de Benedictis F M, Teper A, Green R J, Boner A L, Williams L, Medley H. International Study Group. Effects of 2 inhaled corticosteroids on growth: results of a randomized controlled trial. Arch Pediatr Adolesc Med 2001; 155: 1248–1254
   PubMed Web of Science ®Google Scholar
• Fitsgerald D, Van Asperen P, Mellis C, Honner M, Smith L, Ambler G. Fluticasone propionate 750 micrograms/day versus beclomethasone dipropionate 1500 micrograms/day: comparison of efficacy and adrenal function in paediatric asthma. Thorax 1998; 53: 656–661
   Google Scholar
• Pauwels R A, Yernault J C, Demedts M G, Geusens P. Safety and efficacy of fluticasone and beclomethasone in moderate to severe asthma. Belgian Multicenter Study Group. Am J Respir Crit Care Med 1998; 157: 827–832
   PubMed Web of Science ®Google Scholar
• Bootsma G P, Dekhuizen P N, Festen J, Mulder P G, Swinkels L M, van Herwaarden C L. Fluticasone propionate does not influence bone metabolism in contrast to beclomethasone dipropionate. Am J Respir Crit Care Med 1996; 153: 924–930
   PubMedGoogle Scholar
• Lundback B, Alexander M, Day J, Herbert J, Holzer R, Van Uffelen R, Kesten S, Jones A L. Evaluation of fluticasone propionate (500 micrograms day-1) administered either as dry powder via a Diskhaler inhaler or pressurized inhaler and compared with beclomethasone dipropionate (1000 micrograms day-1) administered by pressurized inhaler. Respir Med 1993; 87: 609–620
   PubMed Web of Science ®Google Scholar
• Fabbri L, Burge P S, Croonenborgh L, Warlies F, Weeke B, Ciaccia A, Parker C. Comparison of fluticasone propionate with beclomethasone dipropionate in moderate to severe asthma treated for one year. International Study Group. Thorax. 1993; 48: 817–823
   PubMed Web of Science ®Google Scholar
• Karakoc F, Karadag B, Kut A, Ersu R, Bakac S, Cebeci D, Dagli E. Comparison of the efficacy and safety of a half dose of fluticasone propionate with beclamethasone dipropionate and budesonide in childhood asthma. J Asthma 2001; 38: 229–237
   Web of Science ®Google Scholar
• Currie G P, Fowler S J, Wilson A M, Sims E J, Orr L C, Lipworth B J. Airway and systemic effects of hydrofluoroalkane fluticasone and beclomethasone in patients with asthma. Thora 2002; 57: 865–868
   PubMed Web of Science ®Google Scholar
• Svendsen U G, Frolund L, Heinig J H, Madsen F, Nielsen N H, Weeke B. [High dose inhaled steroids in the treatment of bronchial asthma. A comparison of the effects of budesonide and beclomethasone dipropionate on pulmonary function, symptoms, bronchial reactivity and adrenocortical function]. [Article in Danish] Ugeskr Laeger 1993; 155: 2197–202
   Google Scholar
• Ebden P, Jenkins A, Houston G, Davis B H. Comparison of two high dose corticosteroid aerosol treatments, beclomethasone dipropionate (1500 micrograms/day) and budesonide (1600 micrograms/day), for chronic asthma. Thorax 1986; 41: 869–874
   PubMed Web of Science ®Google Scholar
• Prahl P. Adrenocortical suppression following treatment with beclomethasone and budesonide. Clin Exp Allergy 1991; 21: 145–146
   PubMedGoogle Scholar
• Gillman S A, Anolik R, Schenkel E, Newman K. One-year trial on safety and normal linear growth with flunisolide HFA in children with asthma. Clin Pediatr (Phila) 2002; 41: 333–340
   PubMed Web of Science ®Google Scholar
• Packe G E, Robb O, Robins S P, Reid D M, Douglas J G. Bone density in asthmatic patients taking inhaled corticosteroids: comparison of budesonide and beclomethasone dipropionate. J R Coll Physicians Lond 1996; 30: 128–132
   Google Scholar
• Gregson R K, Rao R, Murrills A J, Taylor P A, Warner J O. Effect of inhaled corticosteroids on bone mineral density in childhood asthma: comparison of fluticasone propionate with beclomethasone dipropionate. Osteoporos Int 1998; 8: 418–422
   PubMedGoogle Scholar
• Richy F, Bousquuet J, Ehrlich G E, Meunier P J, Israel E, Morii H, Devogelaer J P, Peel N, Haim M, Bruyere O, Reginster J Y. Inhaled corticosteroids effects on bone in asthmatic and COPD patients: a quantitative systematic review. Osteoporos Int 2003; 14: 179–190
   PubMed Web of Science ®Google Scholar
• Birkebaek N H, Esberg G, Andersen K, Wolthers O, Hassager C. Bone and collagen turnover during treatment with inhaled dry powder budesonide and beclomethasone dipropionate. Arch Dis Child 1995; 73: 524–527
   PubMedGoogle Scholar
• Daley-Yates P T, Richards D H. Relationship between systemic corticosteroid exposure and growth velocity: development and validation of a pharmacokinetic/pharmaco-dynamic model. Clin Ther 2004; 26: 1905–1919
   PubMed Web of Science ®Google Scholar
• Sharek P J, Bergman D A. The effect of inhaled steroids on the linear growth of children with asthma: a meta-analysis. Pediatrics 2000; 106: E8
   PubMed Web of Science ®Google Scholar
• Wolthers O D, Pedersen S. Short-term growth during treatment with inhaled fluticasone propionate and beclomethasone dipropionate. Arch Dis Child 1993; 68: 673–676
   PubMed Web of Science ®Google Scholar
• Derendorf H. Pharmacokinetic and pharmacodynamic properties of inhaled corticosteroids in relation to efficacy and safety. Respir Med 1997; 91: 22–28, (suppl A)
   PubMed Web of Science ®Google Scholar
• Martin R J. Therapeutic significance of distal airway inflammation in asthma. J Allergy Clin Immunol. 2002; 109: S447–S460, (Suppl)
   Web of Science ®Google Scholar
• Weiss K B, Liljas B, Schoenwetter W, Schatz M, Luce B R. Effectiveness of budesonide administered via dry-powder inhaler versus triamcinolone acetonide administered via pressurized metered-dose inhaler for adults with persistent asthma in managed care settings. Clin Ther 2004; 26: 102–114
   PubMedGoogle Scholar
• Condemi J J, Chervinsky P, Goldstein M F, Ford L B, Berger W E, Ayars G H, Rogenes P R, Edwards L, Pepsin P J. Fluticasone propionate powder administered through Diskhaler versus triamcinolone acetonide aerosol administered through metered-dose inhaler in patients with persistent asthma. J Allergy Clin Immunol 1997; 100: 467–474
   PubMedGoogle Scholar
• Baraniuk J, Murray J J, Nathan R A, Berger W E, Johnson M, Edwards L D, Srebro S, Rickard K A. Fluticasone alone or in combination with salmeterol vs. triamcinolone in asthma. Chest 1999; 116: 625–632
   PubMedGoogle Scholar
• Weiss K B, Paramore L C, Liljas B, Revicki D A, Luce B R. Patient satisfaction with budesonide turbuhaler versus triamcinolone acetonide administered via pressurized metered-dose inhaler in a managed care setting. J Asthma 2005; 42: 769–776
   PubMed Web of Science ®Google Scholar
• Sorkness C A, LaForce C, Storms W, Lincourt W R, Edwards L, Rogenes P R. Effects of the inhaled corticosteroids fluticasone propionate, triamcinolone acetonide, and flunisolide and oral prednisone on the hypothalamic-pituitary-adrenal axis in adult patients with asthma. Clinical Therapeutics 1999; 21: 353–367
   Google Scholar
• Wilson A M, McFarlane L C, Lipworth B J. Effects of low and high doses of inhaled flunisolide and triamcinolone acetonide on basal and dynamic measures of adrenocortical activity in healthy volunteers. J Clin Endocrinol Metab 1998; 83: 922–925
   PubMedGoogle Scholar
• Argenti D, Shah B, Heald D. A study comparing the clinical pharmacokinetics, pharmacodynamics, and tolerability of triamcinolone acetonide HFA-134a metered-dose inhaler and budesonide dry-powder inhaler following inhalation administration. J Clin Pharmacol 2000; 40: 516–526
   PubMed Web of Science ®Google Scholar
• Wilson A M, Brewster H J, Lipworth B J. Dose-response comparison of systemic bioactivity with inhaled budesonide and triamcinolone acetonide in asthmatic adults. J Allergy Clin Immunol 1998; 102: 751–756
   PubMedGoogle Scholar
• Li J T, Goldstein M F, Gross G N, Noonan M J, Weisberg S, Edwards L, Reed K D, Rogenes P R. Effects of fluticasone propionate, triamcinolone acetonide, prednisone, and placebo on the hypothalamic-pituitary-adrenal axis. J Allergy Clin Immunol 1999; 103: 622–629
   Google Scholar
• Silvers W S, Cohen R, D'Alonzo G. Comparative taste evaluation of aerosolized formulations of triamcinolone acetonide, flunisolide, and flunisolide with menthol. Clin Ther 1993; 15: 988–993
   Google Scholar
• Newhouse A, Knight A, Wang S, Newman K. Comparison of efficacy and safety between flunisolide/AeroChamber and budesonide/turbuhaler in patients with moderate asthma. AER-MD-04 Study Group. Ann Allergy Asthma Immunol 2000; 84: 313–319
   Google Scholar
• Volmer T, Kielhorn A, Weber H H, Wiessmann K J. Cost effectiveness of fluticasone propionate and flunisolide in the treatment of corticosteroid-naive patients with moderate asthma. Pharmacoeconomics 1999; 16: 525–531
   Google Scholar
• Sheikh S, Goldsmith L J, Howell L, Eid N. Comparison of the efficacy of inhaled fluticasone propionate, 880 microg/day, with flunisolide, 1500 μ g/day, in moderate-to-severe persistent asthma. Ann Allergy Asthma Immunol 1999; 83: 300–304
   Google Scholar
• Casale T B, Nelson H S, Stricker W E, Raff H, Newman K B. Suppression of hypothalamic-pituitary-adrenal axis activity with inhaled flunisolide and fluticasone propionate in adult asthma patients. Ann Allergy Asthma Immunol 2001; 87: 379–385
   PubMed Web of Science ®Google Scholar
• Masoli M, Weatherall M, Holt S, Beasley R. Budesonide once versus twice-daily administration: meta-analysis. Respirology 2004; 9: 528–534
   PubMed Web of Science ®Google Scholar
• Gluck J C, Gluck P A. Asthma controller therapy during pregnancy. Am J Obstet Gynecology 2005; 192: 369–380
   PubMed Web of Science ®Google Scholar
• National Asthma Education and Prevention Program Asthma and Pregnancy Working Group. Quick Reference from the Working Group Report on Managing Asthma during Pregnancy: Recommendations for Pharmacologic Treatment, www.nhlbi.nih.gov/health/prof/lung/asthma/astpreg.htm Update 2004
   Google Scholar
• Subbarao P, Dorman S C, Rerecich T, Watson R M, Gauvreau G M, O'Byrne P M. Protection by budesonide and fluticasone on allergen-induced airway responses after discontinuation of therapy. J Allergy Clin Immunol 2005; 115: 745–50
   Google Scholar
• Harmanci E, Colak O, Metintas M, Alatas O, Yurdasiper A. Fluticasone propionate and budesonide do not influence bone metabolism in the long term treatment of asthma. Allergol Immunopathol (Madr) 2001; 29: 22–27
   Google Scholar
• Agertoft L, Pedersen S. A randomized, double-blind dose reduction study to compare the minimal effective dose of budesonide Turbuhaler and fluticasone propionate Diskhaler. J Allergy Clin Immunol 1997; 99: 773–780
   PubMedGoogle Scholar
• Ringdal N, Lundback B, Alton M, Rak S, Eivindson A, Bratten G, Kjaersgaard P. Comparable effects of inhaled fluticasone propionate and budesonide on the HPA-axis in adult asthmatic patients. Respir Med 2000; 94: 482–489
   PubMed Web of Science ®Google Scholar
• Heinig J H, Boulet L P, Croonenborghs L, Mollers M J. The effect of high-dose fluticasone propionate and budesonide on lung function and asthma exacerbations in patients with severe asthma. Respir Med 1999; 93: 613–620
   PubMed Web of Science ®Google Scholar
• Ferguson A C, Spier S, Manjra A, Versteegh F G, Mark S, Zhang P. Efficacy and safety of high-dose inhaled steroids in children with asthma: a comparison of fluticasone propionate with budesonide. J Pediatr 1999; 134: 422–427
   PubMed Web of Science ®Google Scholar
• Corren J, Berkowitz R, Murray J J, Prenner B. Comparison of once-daily mometasone furoate versus once-daily budesonide in patients with moderate persistent asthma. Int J Clin Pract 2003; 57: 567–572
   PubMed Web of Science ®Google Scholar
• Bousquet J, D'Urzo A, Hebert J, Barraza C H, Boulet L P, Suarez-Chacon R, Harnest U, Lundba B, Martinez Morales G, Nieminen M M, Nolop K B, Visser S, Lutsky B N. Comparison of the efficacy and safety of mometasone furoate dry powder inhaler to budesonide Turbuhaler. Eur Respir J 2000; 16: 808–816
   PubMed Web of Science ®Google Scholar
• Reynolds N A, Scott L J. Ciclesonide. Drugs 2004; 64: 511–519
   PubMed Web of Science ®Google Scholar
• Niphadkar P, Jagannath K, Joshi J M, Awad N, Boss H, Hellbardt S, Gadgil D A. Comparison of the efficacy of ciclesonide 160 mug QD and budesonide 200 mug BID in adults with persistent asthma: A phase III, randomized, double-dummy, open-label study. Clin Ther 2005; 27: 1752–1763
   PubMed Web of Science ®Google Scholar
• Boulet L P, Drollmann A, Magyar P, Timar M, Knight A, Engelstatter R, Fabbri L. Comparative efficacy of once-daily ciclesonide and budesonide in the treatment of persistent asthma. Respir Med. 2006; 100: 785–794, Epub 2006 Jan 19
   PubMed Web of Science ®Google Scholar
• Stempel D A, Stanford R H, Thwaites R, Price M J. Cost-efficacy comparison of inhaled fluticasone propionate and budesonide in the treatment of asthma. Clin Ther 2000; 22: 1562–1574
   PubMed Web of Science ®Google Scholar
• Barnes N C, Thwaites R M, Price M J. The cost-effectiveness of inhaled fluticasone propionate and budesonide in the treatment of asthma in adults and children. Respir Med 1999; 93: 402–407
   PubMed Web of Science ®Google Scholar
• Thorsson L, Edsbacker S, Kallen A. Löfdahl C-G. Pharmacokinetics and systemic activity of fluticasone via Diskus and pMDI, and of budesonide via Turbuhaler. Br J Clin Pharmacol 2001; 52: 529–538
   PubMed Web of Science ®Google Scholar
• Derom E, Van Schoor J, Verhaeghe W, Vinken W, Pauwels R. Systemic effects of inhaled fluticasone propionate and budesonide in adult patients with asthma. Am J Respir Crit Care Med 1999; 160: 157–161
   PubMed Web of Science ®Google Scholar
• Harrison T W, Wisniewski A, Honour J, Tattersfield A E. Comparison of the systemic effects of fluticasone propionate and budesonide given by dry powder inhaler in healthy and asthmatic subjects. Thorax 2001; 56: 186–191
   PubMed Web of Science ®Google Scholar
• Agertoft L, Pedersen S. Short-term knemometry and urine cortisol excretion in children treated with fluticasone propionate and budesonide: a dose response study. Eur Respir J. 1997; 10: 1507–1512
   PubMed Web of Science ®Google Scholar
• Acun C, Tomac N, Ermis B, Onk G. Effects of inhaled corticosteroids on growth in asthmatic children: a comparison of fluticasone propionate with budesonide. Allergy Asthma Proc 2005; 26: 204–206
   PubMed Web of Science ®Google Scholar
• Masoli M, Weatherall M, Holt S, Beasley R. Systematic review of the dose-response relation of inhaled fluticasone propionate. Arch Dis Childhood 2004; 89: 902–907
   PubMed Web of Science ®Google Scholar
• Samaras K, Pett S, Gowers A, McMurchie M, Cooper D A. Iatrogenic Cushing's syndrome with osteoporosis and secondary adrenal failure in human immunodeficiency virus-infected patients receiving inhaled corticosteroids and ritonavir-boosted protease inhibitors: six cases. J Clin Endocrinol Metab 2005; 90: 4394–4398
   PubMed Web of Science ®Google Scholar
• O'Connor B, Bonnaud G, Haahtela T, Luna J M, Querfurt H, Wegener T, Lutsky B N. Dose-ranging study of mometasone furoate dry powder inhaler in the treatment of moderate persistent asthma using fluticasone propionate as an active comparator. Ann Allergy Asthma Immunol 2001; 86: 397–404
   PubMed Web of Science ®Google Scholar
• Wardlaw A, Larivee P, Eller J, Cockcroft D W, Ghaly L, Harris A G. Efficacy and safety of mometasone furoate dry powder inhaler vs. fluticasone propionate metered-dose inhaler in asthma subjects previously using fluticasone propionate. Ann Allergy Asthma Immunol 2004; 93: 49–55
   PubMed Web of Science ®Google Scholar
• Lee D K, Fardon T C, Bates C E, Haggart K, McFarlane L C, Lipworth B J. Airway and systemic effects of hydrofluoroalkane formulations of high-dose ciclesonide and fluticasone in moderate persistent asthma. Chest 2005; 127: 851–860
   PubMed Web of Science ®Google Scholar
• Derom E, Van De Velde V, Marissens S, Engelstätter R, Vinken W, Pauwels R. Effects of inhaled ciclesonide and fluticasone propionate on cortisol secretion and airway responsiveness to adenosine 5'monophosphate in asthmatic patients. Pulm Pharmacol Ther 2005; 18: 328–336
   PubMed Web of Science ®Google Scholar
• Lipworth B J, Kaliner M A, LaForce C F, Baker J W, Kaiser H B, Amin D, Kundu S, Williams J E, Engelstätter R, Banerji D D. Effect of ciclesonide and fluticasone on hypothalamic-pituitary-adrenal axis function in adults with mild-to-moderate persistent asthma. Ann Allergy Asthma Immunol 2005; 94: 465–472
   PubMed Web of Science ®Google Scholar
• Richter K, Kanniess F, Biberger C, Nave R, Magnussen H. Comparison of the oropharyngeal deposition of inhaled ciclesonide and fluticasone propionate in patients with asthma. J Clin Pharmacol 2005; 45: 146–152
   PubMed Web of Science ®Google Scholar
• Fardon T C, Lee D K, Haggart K, McFarlane L C, Lipworth B J. Adrenal suppression with dry powder formulations of fluticasone propionate and mometasone furoate. Am J Resp Crit Care Med 2004; 170: 960–966
   PubMed Web of Science ®Google Scholar
• Affrime M B, Kosoglou T, Thonoor C M, Flannery B E, Herron J M. Mometasone furoate has minimal effects on the hypothalamic-pituitary-adrenal axis when delivered at high doses. Chest 2000; 118: 1538–1546
   PubMed Web of Science ®Google Scholar
• Belvisi M G, Bundschuh D S, Stoeck M, Wicks S, Underwood S, Battram C H, Haddad E, Webber S E, Foster M L. Preclinical profile of ciclesonide: a novel corticosteroid for the treatment of asthma. J Pharmacol Exp Ther 2005; 314: 568–574
   PubMed Web of Science ®Google Scholar
• Szefler S, Rohatagi S, Williams J, Lloyd M, Kundu S, Banerji D. Ciclesonide: a novel inhaled steroid, does not affect hypothalamic-pituitary-adrenal axis function in patients with moderate-to-severe persistent asthma. Chest 2005; 128: 1104–1114
   PubMed Web of Science ®Google Scholar
• Todd G R, Acerini C L, Ross-Russell R, Zahra S, Warner T J, McCance D. Survey of adrenal crisis associated with inhaled corticosteroids in the United Kingdom. Arch Dis Child 2002; 87: 457–461
   PubMed Web of Science ®Google Scholar
• Affrime M B, Cuss F, Padhi D, Wirth M, Pai S, Clement R P, Lim J, Kantesaria B, Alton K, Cayen M N. Bioavailability and metabolism of mometasone furoate following administration by metered-dose and dry-powder inhalers in healthy human volunteers. J Clinical Pharmacol 2000; 40: 1227–1236
   PubMed Web of Science ®Google Scholar
• Valotis A, Högger P. Significant receptor affinities of metabolites and a degradation product of mometasone furoate. Respir Res 2004; 5: 7, http://respiratory.research.com/content/5/1/7 Open access online at
   PubMedGoogle Scholar
• Sharpe M, Jarvis B. Inhaled mometasone furoate: a review of its use in adults and adolescents with persistent asthma. Drugs 2001; 61: 1325–1350
   PubMed Web of Science ®Google Scholar
• Karpel J P, Busse W W, Noonan M J, Monahan M E, Lutsky B, Staudinger H. Effects of mometasone furoate given once daily in the evening on lung function and symptom control in persistent asthma. Ann Pharmacother 2005; 39: 1977–1983
   PubMed Web of Science ®Google Scholar
• D'Urzo A, Karpel J P, Busse W W, Boulet L P, Monahan M E, Lutsky B, Staudinger H. Efficacy and safety of mometasone furoate administered once-daily in the evening in patients with persistent asthma dependent on inhaled corticosteroids. Curr Med Res Opin 2005; 21: 1281–1289
   PubMed Web of Science ®Google Scholar
• Masoli M, Weatherall M, Beasley R. Fluticasone given once versus twice a day: meta-analysis. Respirology 2005; 10: 183–188
   PubMed Web of Science ®Google Scholar
• Rohatagi S, Arya V, Zech K, Nave R, Hochhaus G, Jensen B K, Barrett J S. Population pharmacokinetics and pharmacodynamics of ciclesonide. J Clinical Pharmacol 2003; 43: 365–378
   PubMed Web of Science ®Google Scholar
• Christie P. Ciclesonide: a novel inhaled corticosteroid for asthma. Drugs Today (Barc) 2004; 40: 569–576
   PubMed Web of Science ®Google Scholar
• Rohatagi S, Krishnaswami S, Pfister M, Sahasranaman S. Model-based covariate pharmacokinetic analysis and lack of cortisol suppression by the new inhaled corticosteroid Ciclesonide using a novel cortisol release model. Am J Ther 2005; 12: 385–397
   Google Scholar
• Chapman K R, Patel P, D'Urzo A D, Alexander M, Mehra S, Oedekoven C, Engelstätter R, Boulet L P. Maintenance of asthma control by once-daily inhaled ciclesonide in adults with persistent asthma. Allergy 2005; 60: 330–337
   PubMed Web of Science ®Google Scholar
• Pearlman D S, Berger W E, Kerwin E, LaForce C, Kundu S, Banerji D. Once-daily ciclesonide improves lung function and is well tolerated by patients with mild-to-moderate persistent asthma. J Allergy Clin Immunol 2005; 116: 1206–1212
   PubMed Web of Science ®Google Scholar
• Zitt M J. Properties of the ideal corticosteroid therapy. Allergy Asthma Proc 2005; 26: 173–182
   PubMed Web of Science ®Google Scholar
• Gauvreau G M, Boulet L P, Postma D S, Kawayama T, Watson R M, Duong M L, Deschesnes F, DeMonchy J GR, O'Byrne P M. Effect of low-dose ciclesonide on allergen-induced responses in subjects with mild allergic asthma. J Allergy Clin Immunol 2005; 116: 285–291
   PubMed Web of Science ®Google Scholar
• Nave R, Drollmann A, Steinijans V W, Zech K, Bethke T D. Lack of pharmacokinetic drug-drug interaction between ciclesonide and erythromycin. Int J Clin Pharmacol Ther 2005; 43: 264–270
   PubMed Web of Science ®Google Scholar
• Product Information Asmanex Twisthaler 220 mcg (mometasone furoate inhalation powder). Schering Corporation Kenilworth, NJ 07033 USA. Rev. 5/05 B-26796016
   Google Scholar